Drugs / 68Ga-PTF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05222269 | Oct 2022 → Jan 2023 | central nervous system non-hodgkin lymphoma | Pentixapharm AG | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-PTF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222269 ↗ |
| Route | Intravenous | “68Ga-PTF will be injected intravenously” NCT05222269 ↗ |